BioNTech's overall survival data show promise of potential Keytruda killer in breast cancer
Cardiff Oncology’s onvansertib shows efficacy in Phase 2 colorectal cancer trial
What’s next for 23andMe?
GSK pens $45M Relation-ship with AI biotech to identify fibrotic, osteoarthritis targets
*please scroll down for all the latest news*
